A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Study identifier:D7400C00006

ClinicalTrials.gov identifier:NCT04594642

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Medical condition

B-cell Non Hodgkin Lymphoma

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD0486 IV

Sex

All

Estimated Enrollment

231

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 02 Mar 2021
Estimated Primary Completion Date: 15 Jan 2027
Estimated Study Completion Date: 15 Jan 2027

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

N/A

Inclusion and exclusion criteria